Activity

Activity ID

4479

Expires

October 3, 2020

Format Type

Journal-based CME

CME Credit

1

Fee

$30
CME Provider

JAMA

Description

This JAMA Insights article explains cell-free circulating tumor DNA and its utility in noninvasive cancer detection and characterization, prediction of treatment response, monitoring of disease relapse, and identification of mechanisms of resistance to targeted therapies.

doi:10.1001/jama.2017.12131

Disclaimers
1. This activity is accredited by the American Medical Association.
2. This activity is free to AMA members.

Register for this Activity

ABMS Member Board Approvals by Type
More Information
Commercial Support?
No

NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.

Educational Objectives

To understand technology used for establishing diagnoses based on analysis of circulating DNA.

Keywords

Cancer Biomarkers, Oncology, Surgical Oncology, Pathology and Laboratory Medicine, Targeted and Immune Cancer Therapy

Competencies

Medical Knowledge

CME Credit Type

AMA PRA Category 1 Credit

Additional Information

doi:10.1001/jama.2017.12131

View All Activities by this CME Provider

The information provided on this page is subject to change. Please refer to the CME Provider’s website to confirm the most current information.